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Abstract. MCI is a nosological entity proposed as an intermediate state between normal aging and dementia. The syndrome can
be divided into two broad subtypes: amnestic MCI (aMCI) characterized by reduced memory, and non-amnestic MCI (naMCI)
in which other cognitive functions rather than memory are mostly impaired. aMCI seems to represent an early stage of AD,
while the outcomes of the naMCI subtypes appear more heterogeneous -including vascular dementia, frontotemporal dementia
or dementia with Lewy bodies- but this aspect is still under debate. MCI in fact represents a condition with multiple sources of
heterogeneity, including clinical presentation, etiology, and prognosis. To improve classification and prognosis, there is a need
for more sensitive instruments specifically developed for MCI as well as for more reliable methods to determine its progression
or improvement. Current clinical criteria for MCI should be updated to include restriction in complex ADL; also the diagnostic
and prognostic role of behavioral symptoms and motor dysfunctions should be better defined. A multidisciplinary diagnostic
approach including biological and neuroimaging techniques may probably represent the best option to predict the conversion from
MCI to dementia. In this review we discuss the most recent aspects related to the epidemiological, clinical, neuropathological,
neuroimaging, biochemical and therapeutic aspects of MCI, with specific attention to possible markers of conversion to dementia.
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INTRODUCTION
Over the last decade a great amount of scientific ef-
fort has focused on the gray area between cognitively
normal aging and dementia in order to define what can
still be considered normal at different ages and what,
on the other hand, is already the prodromal phase of an
clinically disclosed dementia. The concept of “cogni-
tive impairment not yet dementia” has been depicted by
different definitions with variable prognosis (Table 1).
Among them, Mild Cognitive Impairment (MCI) has
become the term most frequently used and defined by
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slight impairment in cognitive functions with otherwise
normal function in the activities of daily living [103].
The original criteria of MCI were related to an
amnestic form, lately defined as aMCI, characterized
by the presence of isolated memory impairment, mem-
ory complaint, relatively intact activities of daily liv-
ing, normal general cognitive function and absence of
dementia [99]. Using this definition in population stud-
ies, it was shown that aMCI constituted only a rela-
tively small group, compared with all individuals with
a much broader form of mild cognitive deficits in oth-
er cognitive functions such as language, attention, vi-
suospatial skills, and executive functioning [46,65,70,
111]. Thus, Petersen [103] revised the original criteria
and four different MCI subtypes have been proposed:
(1) the former aMCI; (2) single non memory MCI (sn-
mMCI), with isolated impairment of a cognitive do-
main other than memory; (3) multiple domain amnes-
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Table 1
Clinical terms proposed to define cognitive impairment not yet dementia
Term Initial description Diagnostic criteria
Age-associated memory
impairment
Crook and co-workers [28] Subjective memory impairment with objective memory impairment
compared with that of a young adult
Late-life forgetfulness Blackford, LaRue [19] Age-associated memory impairment plus age-adjusted deficits in four
or more specific cognitive tests
Mild cognitive decline ICD-10 [128] Impairments in cognitive tests of learning, memory, or concentration
secondary to defined illness
Questionable dementia Morris [91] Scoring 0.5 at Clinical Dementia Rating scale
Aging-associated cognitive
decline
Levy [67] Age-adjusted impairment on any cognitive task
Mild neurocognitive decline DSM IV [2] Impairments in memory, learning, perceptual-motor, linguistic, or exec-
utive functioning
Cognitive impairment–no
dementia
Graham and co-workers [51] Impairments in memory, learning, perceptual-motor, linguistic or exec-
utive functioning in the absence of clinically defined dementia
Mild Cognitive dysfunction Johansson and Zarit [59] Dysfunction according to five cognitive tests
MCI Petersen and co-workers [99] Subjective complaint of memory impairment with objective memory
impairment adjusted for age and education in the absence of dementia.
The definition was then expanded to include four clinical MCI subtype
Subclinical cognitive
impairment
Ritchie and co-workers [112] Scoring below a specific scor on the D`ete`rioration Cognitive Observe`e,
a test sensitive to early change in cognitive functioning
Cognitive impairment, no
dementia
De Ronchi and co-workers [34] Scoring 2 or more S.D. below the mean score of MMSE, corrected for
age and education, calculated among the non-demented people
Modified from De Carli [32].
tic MCI (mdMCI+), characterized by a slight impair-
ment of multiple cognitive domains including memory;
(4) multiple domains non amnestic MCI (mdMCI−),
with a slight impairment of multiple cognitive domains
but without memory deficits. However, there is still a
lack of consensus on what types of cognitive tests, how
many, and what thresholds or cut-off should be used to
support or corroborate the diagnosis of MCI [72].
Longitudinal studies suggested that MCI represents
a condition at high risk of progression to dementia, but
rates of conversion vary among studies. Progression
to dementia generally appears to be higher in clinic-
based studies with a yearly incidence of about 10–15%.
Instead, population-based studies report lower rates,
ranging from 5 to 10% per year [32,95]. Moreover,
in population-based studies, a significant rate of rever-
sion (20–25%) from mild cognitive impairment to nor-
mal cognition and functioning was observed [94,111].
The discrepancy of progression rates to dementia be-
tween clinic- vs population-based studies probably re-
flects differences in population characteristics, length
of follow-up and definition of cognitive impairment.
Furthermore, the possibility of selection bias should be
taken into account when examining data from clinic-
based study.
According to the proposed four clinical subtypes of
MCI, it is conceivable that they differ in etiology and
outcome. In fact, aMCI and mdMCI+ are considered
to have a high likelihood of progression to Alzheimer’s
disease (AD), while snmMCI and mdMCI− are as-
sumed to convert more frequently to non-AD demen-
tia [12,98,103]. This aspect was recently confirmed
by a German longitudinal study showing that, at six-
year follow-up, subjects with mdMCI−were more like-
ly to progress to a non-AD dementia, and those with
mdMCI+ converted mostly to AD [21]. Conversely,
data from an Austrian community birth cohort study
found that, after thirty months of follow-up, the aMCI
subtype evolved towards both AD and non-AD demen-
tia and many patients developed AD from non amnestic
MCI [42]. According to these as well as to previous
data [65,89,104,111], MCI appears to be an extremely
heterogeneous clinical entity in terms of etiology, clini-
cal presentation and outcome and much effort is needed
for developing a more uniform diagnostic classification
and better defined operational criteria.
EPIDEMIOLOGY
Prevalence and Incidence of MCI
Population-based studies in older adults (age60 or
65 years) performed in North America and Europe
reported a prevalence of MCI ranging from 11% to
17% [35,46,51,70,111], higher than previously report-
ed prevalence of dementia (6–8%) [35,51,70].
Prevalence of the aMCI subtype was estimated be-
tween 3 and 5% [70,76]. Likewise, in the Canadian
Study of Health and Aging, the prevalence of “circum-
E. Mariani et al. / Mild Cognitive Impairment: A Systematic Review 25
scribed memory loss” or “isolated memory deficit”, a
clinical construct similar to aMCI, was about 5% [43].
Very few studies addressed this aspect in the oldest old
population [104].
Regarding the incidence rates, the few studies pub-
lished to date considered only the aMCI subtype, with
a range from 9.9 to 21.5 per 1000 person per year in
people older than 65 years [65,120].
Most of the variability in prevalence and incidence
estimates of MCI is probably due to the different oper-
ational criteria used rather than to the characteristics of
the studied populations.
Risk Factors for MCI
Not many studies have prospectively addressed the
role of putative risk factors for MCI. Three short-term
longitudinal studies, carried out in subjects with MCI,
identified as risk factors older age, low education, be-
ing African American, presence of apolipoprotein E
ε4 allele (ApoE 4), cortical atrophy at neuroimaging,
signs or symptoms of vascular diseases and depres-
sion [14,71,123]. In a recent three-year prospective
study, the authors found that a previous diagnosis of
psychosis, hip fracture and polypharmacy increased
the risk of cognitive impairment in non demented sub-
jects, independent of subsequent development of de-
mentia [89]. Furthermore, three long-term prospec-
tive studies described midlife alcohol drinking,elevated
serum cholesterol, high diastolic blood pressure, ApoE
ε4, and white matter hyperintensities as risk factors for
MCI in late life [8,31,63].
Prevalence of vascular risk factors in different MCI
subtypes was evaluated in more than two hundred
subjects with MCI collected in the ReGAl project
(Rete Geriatrica Alzheimer – Geriatric Network on
Alzheimer’s disease), the largest longitudinal Italian
multicentric clinical-based study on aging and demen-
tia, promoted by the Italian Society of Gerontology
and Geriatrics (SIGG). This project, initiated in 2001
and still ongoing, involves 35 Geriatric Memory Clin-
ics all over Italy and is coordinated by the Institute
of Gerontology and Geriatrics of the University of Pe-
rugia. Methods of the ReGA1 project have been de-
scribed in more detail elsewhere [106]. From the anal-
ysis of collected data, a different vascular risk profile
among different MCI subtypes was found,with subjects
with snmMCI having a higher prevalence of ischemic
heart disease and of TIA/stroke, a higher Hachinski is-
chemic score, and a higher prevalence of white matter
lesions on CT/MRI scan compared to aMCI (submitted
paper). These data suggest that, as with dementia, the
heterogeneity of clinical expression in different MCI
subtypes is probably related to a different pathogene-
sis, that may include both degenerative and vascular
factors.
Mortality
There is little information on mortality rate in MCI
and in the different MCI subtypes. A prospective com-
munity study of the Mayo Clinic Group demonstrated
an increased mortality in subjects with aMCI compared
to normal control subjects over a six-year follow-up.
Mortality was greater in mdMCI than in aMCI [56].
A recent review reported a non significant increase in
mortality for subjects with MCI compared to cognitive-
ly intact subjects [51]. However, only few studies are
available on this issue, and a comparison of the liter-
ature is problematic, due to variations in criteria and
methodology.
COGNITIVE STATUS
Currently, the diagnosis of MCI is mainly based on
results at neuropsychological tests. The large variabil-
ity due to measurement errors, lack of appropriate nor-
mative data and difference in sensitivity and specifici-
ty of the neuropsychological batteries more commonly
used, can cause misclassification. In the original MCI
criteria, Petersen and collaborators [99] suggested a
cut-off of at least 1.5 standard deviations below the age-
and education-adjusted values for defining as “mild”
the impairment in different cognitive domains. Among
cognitive tasks, neuropsychological tests assessing de-
layed recall, executive functions and selective atten-
tion have been found to better predict the conversion
of MCI to dementia [3,27,122], but with a sensitivi-
ty and specificity usually lower than 70% [88]. Con-
versely, it was recently shown that the performance at
the CERAD-10-word list (CERAD-CWL), a task eval-
uating long-term verbal recall, was highly sensitive for
detecting MCI [118]. Using correspondent analysis to
derive a weighted score for each subject from their item
responses over the three immediate- and one delayed-
recall trials of the CERAD-CWL, the authors found
that comparing MCI versus normal subjects, accuracy
was 97%, sensitivity 94% and specificity 89%. For
MCI/mild dementia versus normal subjects, accuracy
was 98%, sensitivity 96% and specificity 91%.
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Specific cognitive batteries for MCI have not been
proposed yet, although there is a need for sensitive,
user-friendly, MCI cognitive screening tests for clini-
cians. Recently, the Montreal Cognitive Assessment
(MOCA) has been developed [93]. This test represents
a brief cognitive screening tool with high sensitivity
and specificity for detecting MCI, as currently concep-
tualized, in patients performing in the normal range on
the Mini-Mental State Examination. With the same
purpose, Li and collaborators [68] showed that using
a brief instrument combining a single-item informant
report of the memory problem and a four-item Instru-
mental Activities of Daily Living (IADL) scale, it is
possible to differentiate MCI and mild AD from normal
aging with high accuracy, sensitivity and specificity.
FUNCTIONAL STATUS
The original criteria for MCI provided for intact ac-
tivities of daily living (ADL), but the current recom-
mendations indicate that basic ADL (BADL) should
be mainly preserved, and that a “minimal impairment”
in instrumental ADL (IADL) may be accepted [129].
However, to date non specific instruments for evaluat-
ing complex activities of daily living in MCI have been
proposed, and there is a need for a consensus regarding
the degree of functional decline that can be considered
acceptable in the frame of MCI definition [49]. An-
alyzing the functional characteristics of subjects with
MCI collected in the ReGAl study, it was found that
subjects with MCI had a more severe IADL disability
than cognitively healthy elderly controls,particularly in
shopping, self-administration of drugs, and in handling
economy. These IADL disabilities were significantly
associated with the degree of cognitive impairment, but
not with the somatic comorbidity [40]. Consistent with
these findings, Bennett and collaborators [18], in their
study population of MCI, did not detect impairment in
BADL while the IADL impairment was highly preva-
lent, with 53% of subjects needing help with house-
work and 43% with shopping. Similarly, in another
study, it was found that MCI patients have limitations in
everyday tasks that involve either memory (i.e. finding
things at home, keeping appointments, and remember-
ing information from a conversation or from television)
or complex reasoning (i.e., checking the bank account,
shopping, organizing travel), whereas they have normal
abilities on basic ADL [97].
Furthermore, recent data suggest that the inclusion
of IADL restriction in MCI criteria improves the pre-
diction of a subsequent dementia as well as the sta-
bility of MCI condition over time [96]. Incorporating
difficulties in performing the activities of daily living
with the alterations in non-memory cognitive functions
has been found to ameliorate the original diagnostic
algorithm for MCI and better detect subjects at risk of
convertion to dementia [11].
NEUROPSYCHIATRIC SYMPTOMS
Neuropsychiatric symptoms (NPS) have not been
included in the diagnostic criteria and only recently
some studies described the neuropsychiatric features of
MCI [24,39,44,48,57,73]. According to these studies,
frequency of NPS in MCI ranges from 35% to 59%,
substantially mimicking the neuropsychiatric involve-
ment of AD. In particular, anxiety-depressive symp-
toms, apathy, irritability and agitation appear to be the
most common NPS in both conditions [39,73,74]. A
similar spectrum of affective disorders was observed in
subjects with MCI in the ReGAl project: depression
and anxiety were, in fact, the most common symptoms,
observed in about 33% of subjects, followed by apathy
(22%) and irritability (20%). Their presence was as-
sociated with a more severe somatic comorbidity and
functional disability, both in ADL and IADL [77].
Among affective disorders, depression has been de-
scribed as a predictor for a subsequent cognitive de-
cline [15,131] and as an independent risk factor for
the development of MCI [14]. Depression predicted
a faster cognitive deterioration in subjects with aMCI,
increasing the risk of conversion to dementia [87].
Recent data showed that a previous diagnosis of psy-
chosis independently increases the risk of MCI [89];
furthermore MCI subjects who convert to AD have
a higher frequency of apathy compared to non-
converters [113].
NEUROPATHOLOGY
Relatively few data on the neuropathological fea-
tures of MCI are present in the literature. Results from
the Religious Order Study showed that more than one
half of persons with MCI met the National Institute
on Aging-Reagan criteria for AD. However, about one
third of them had also cerebral infarctions [17]. Sim-
ilarly, in a recent study describing the neuropatholog-
ical features of aMCI the authors found that many pa-
tients did not fulfil the neuropathologic criteria for AD
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but their pathologic findings showed characteristics of
a transitional state of evolving AD. Although medial
temporal lobe structures, as typical of subjects with
AD, were involved in all aMCI, they had also other
concomitant pathologic abnormalities, including argy-
rophilic grain disease, hippocampal sclerosis, and vas-
cular lesions [100]. Presence of neurofibrillary tangles
rather than amyloid deposition seems to be more pre-
minent in MCI compared to cognitively healthy con-
trols, with the highest values in early AD. The num-
bers of neurofibrillary tangles in entorhinal cortex and
hippocampus are related to the progressive memory
loss. This suggests a continuum of neurofibrillary tan-
gle pathologies underlying transition between normal
aging, MCI and early AD [79].
NEUROIMAGING
Several neuroimaging studies described the struc-
tural and functional changes of subjects with MCI. The
most consistent data derived from structural magnet-
ic resonance imaging (MRI). Subjects with MCI show
atrophy of the entorhinal and hippocampo-amygdala
regions with an intermediate degree between that ob-
served in normal aging and in AD [116]. Rusinek et
al. [115] reported that the medial temporal lobe atro-
phy rate was the most significant predictor of conver-
sion from normal aging to MCI, with 91% specificity
and 85% sensitivity. In addition to hippocampal atro-
phy, alteration of parahippocampal white matter fibers
has been suggested as contributing to memory decline
in elderly individuals with MCI by partially discon-
necting the hippocampus from incoming sensory in-
formation [121]. Concerning specific MCI subtypes,
recent data show that mdMCI and aMCI have distinct
brain structural abnormalities. While both groups have
mesial temporal and cortical volume loss, those with
aMCI have a more severe involvement of the mesial
temporal structures and less of the neocortical hetero-
modal association cortices than mdMCI [16]. Howev-
er, quantification of brain volumes has not been stan-
dardized for clinical use, and volumetric MRI is not
currently included in the diagnostic work-up of MCI.
Compared to MRI, a small number of functional
imaging studies have been conducted in MCI. Data ob-
tained using [18F]-fluorodeoxyglucose positron emis-
sion tomography (FDG-PET) showed that the reduc-
tion in glucose metabolism in the hippocampus sig-
nificantly improved diagnostic accuracy for MCI over
MRI hippocampal volumetric measures (85% versus
73%) [30].
There have been increasing efforts to develop diag-
nostic neuroimaging methods able to detect amyloid or
tau proteins. Radiolabelled PET tracers, which bind
to amyloid plaques and neurofibrillary tangles in vitro,
have been a matter of intense investigation. A recent
study conducted with 2-(1-{6-[(2-[F-18]fluoroethyl)
(methyl)amino]-2-naphthyl}ethylidene) malononitrile
(FDDNP) PET showed that the global FDDNP bind-
ing (average of the values for temporal, parietal, pos-
terior cingulated, and frontal regions) in MCI subjects
was significantly higher than in controls and lower than
in AD. These data suggest that FDDNP-PET is able
to differentiate MCI from controls and AD, probably
more accurately than FDG-PET or volumetric MRI
measures [119].
Another recent technique previously used in AD and
then applied to MCI, is proton magnetic resonance
spectroscopy (1H-MRS), a useful tool for the in vivo
assessment of several biochemical compounds of the
brain. Data from Catani and collaborators [23], showed
that subjects with MCI had an alteration in myo-
Inositol signal, with significantly higher value of myo-
Inositol/Creatine ratio (mI/Cr) than control subjects and
similar to subjects with mild AD, who instead had a
significant reduction of N -Acetyl-Aspartate/Creatine
ratio (NAA/Cr) level in the paratrigonal white matter
compared to controls. Consistently, Kantarci et al. [60]
showed in the gray matter of posterior cingulate gyrus
an increased mI/Cr level in subjects with MCI com-
pared to normal controls and higher still in patients with
AD, as well as a lower NAA/Cr in AD compared to
both MCI and cognitively normal subjects. On the con-
trary, Chantal et al. [25] suggested that the increased mI
signal is a neurochemical abnormality associated with
AD but not with MCI, with a significant increased mI
signal in patients with AD compared to both MCI and
control subjects.
BIOMARKERS
Biomarkers other than those obtained from struc-
tural or functional neuroimaging were widely studied
in subjects with early AD. Typical neuropathological
lesions of AD are senile plaques, constituted by the
beta-amyloid protein, and neurofibrillary tangles, origi-
nating from hyperphosphorylated tau protein [5]. Over
the last years, many efforts have been made in the iden-
tification of potential biomarkers for both MCI and de-
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mentia from the analysis of cerebral spinal fluid (CSF).
CSF biomarkers for MCI include total tau protein (T-
τ ), phosphorylated tau protein (P-τ ) and amyloid be-
ta 1-42 protein (Aβ-42) [5,116]. Several studies have
found high CSF T-τ and P-τ , and low CSF Aβ-42 in
subjects with MCI, with sensitivity figures similar to,
or slightly lower than, those found in AD cases [6,7,9,
66].
These biomarkers also showed a high sensitivity in
differentiating early AD from normal aging, depression
and Parkinson’s disease, but lower specificity versus
other dementias, such as fronto-temporal and Lewy
body dementia [5].
Recently, it was suggested that also plasma Aβ-42/
Aβ-40 ratio may be a useful marker for identifying
cognitively healthy elderly subjects who are at increas-
ing risk for developing MCI and AD, reflecting the
extent to which there has been selective aggregation
and deposition of Aβ-42 in the brain [50]. The au-
thors postulated that CSF Aβ-42, as well as plasma
Aβ-42 levels, decline in parallel as Aβ-42 deposits in
the brain, and, because Aβ-42 aggregation and deposi-
tion precedes MCI and AD, most subjects who develop
MCI/AD have a low Aβ-42/ Aβ-40 ratio several years
before the diagnosis of the disease.
There is also evidence for a role of oxidative stress in
the pathogenesis of MCI [22,62,78,83,107]. Increased
levels of the isoprostane 8,12-iso-PF2a-VI -a specific
marker of in vivo lipid peroxidation [108] – were found
to be significantly elevated in CSF, plasma and urine
of MCI subjects compared with controls [107], sug-
gesting that lipid peroxidation may be an early event
in the pathogenesis of the disease. Nevertheless, ad-
ditional studies on the presence of elevated levels of
biomarkers of oxidative stress in MCI are warranted,
also in light of the discrepancies otherwise observed be-
tween brain/CSF versus plasma/urine F2-isoprostanes
and F4-neuroprostanes levels [90,109].
An increased DNA oxidative damage in peripheral
leukocytes, previously reported in AD subjects [81,82],
has been recently found in MCI [85], as well as in
nuclear and mitochondrial DNA isolated from frontal,
parietal and temporal brain lobes [127].
Subjects with MCI showed also lower levels of non
enzymatic antioxidants (vitamin A, vitamin C, vitamin
E, uric acid and of the carotenoids lutein, zeaxanthin
and β-carotene) and lower activities of enzymatic an-
tioxidants (plasma and erythrocyte superoxide dismu-
tase, plasma glutathione peroxidase) as compared to
controls [110]. Similarly, plasma total antioxidant ca-
pacity (including uric acid, glutathione, thiol groups,
vitamins, glutathione peroxidase, superoxide dismu-
tase and catalase) was shown to be significantly re-
duced in MCI subjects as compared to age-matched
controls [53].
Finally, it was recently found a decrease in the per-
centage of total lymphocytes and a concomitant in-
crease in granulocytes in MCI subjects compared to
controls [75], consistent with evidences of a decrease
in the proliferative ability of lymphocytes [117], and
of increased granulocyte activity [69] in AD patients,
suggesting an inflammatory state specific not only for
AD, but also for MCI.
PREDICTORS OF PROGRESSION OF MCI TO
DEMENTIA
Clinical, imaging, genetic and CSF aspects have
been widely examined as possible markers in MCI in
order to detect subjects at greater risk of conversion
to dementia. However, most of the studies describe
subjects with aMCI, with negligible information for
other MCI subtypes. Some authors have also tried to
combine different predictors to increase the accuracy
of conversion to AD or other dementias.
Neuropsychological predictors of conversion include
performance on specific cognitive tests, particular-
ly those assessing delayed recall and executive func-
tions [3,27,122]. However, neuropsychological tests
rarely overcome 70% sensitivity and specificity [88].
Conversely, Visser an colleagues [126] found that
scores on memory tests predicted progression to AD
with 88% accuracy, and the addition of hippocampal
volume measure increased accuracy to 100%. Other
clinical aspects considered as predictors of conversion
are IADL disability [96], depressive symptoms [87],
and coexistent motor dysfunctions. For this aspect, in a
recent longitudinal cohort study in subjects with MCI,
impaired motor performance of lower limbs, parkinso-
nian gait, and bradykinesia increased the risk of AD
after a ten-year follow-up [1].
Hippocampal or entorhinal atrophy on MRI are the
most commonly used neuroradiological markers of
conversion from MCI to dementia [116]. Subjects with
MCI who converted to AD during two-year follow-up,
in fact, had a greater atrophy in the left entorhinal cor-
tex, bilateral superior temporal gyri, and right inferior
frontal gyrus compared to nonconverters [16]. Simi-
larly, data from the Rotterdam study showed that hip-
pocampal and amygdala volumes were strongly asso-
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ciated with the risk of dementia in cognitively intact
elderly people after six-year follow-up [33].
Recent promising neuroimaging techniques for eval-
uating conversion from MCI to dementia include PET
and 1H-MRS. Reduced metabolic activity in temporo-
parietal cortices [10] or in the posterior cingulate
gyrus [36], as shown in FDG-PET scans, have been as-
sociated with a greater risk of progression to dementia.
Further, the highest degree of accuracy (>90%) was
achieved by means of PET scan plus either memory
performance [4] or APOE ε4 genotype [92].
A recent study performed with 1H-MRS found that
subjects with aMCI who convert to AD over one year
had a significant difference of the NAA/Cr ratio in the
left hemisphere with respect to both non-convertersand
healthy controls [84]. These data confirmed previous
evidence suggesting that decreased NAA/Cr levels pre-
dict future conversion to AD in subjects with MCI [26,
86]. It was recently reported that while there were no
differences in NAA/Cr, Cho/Cr and mI/Cr at baseline
between stable MCI and MCI who converted to AD
after a median follow-up period of thirteen months, the
annualized rate of change in Cho/Cr ratio was greater in
stable MCI compared to converter MCI and cognitively
normal controls, suggesting a possible compensatory
mechanism in stable MCI [61].
CSF biomarkers represent to date those with the
highest accuracy for the conversion from MCI to AD.
Three biomarkers – T-τ protein, P-τ protein and Aβ-42
protein – have been evaluated in many scientific reports.
Subjects with MCI who lately developed AD had an
increased baseline CSF concentration of T-τ and P-τ ,
whereas the level of Aβ-42 protein was decreased. In
addition, recent studies provided evidence that reduc-
tion in the Aβ-42/P-τ ratio may help to identify those
patients with MCI who later develop AD [5,116]. How-
ever, the clinical follow-up in these studies has been
short and data have been collected in small selected
hospital samples. To overcome this issue, data from a
recent article, carried out in 180 consecutive individ-
uals with MCI over a four- to six-year of follow-up,
showed that subjects with MCI who had pathological
concentrations of T-τ and Aβ-42 proteins at baseline
are at increased risk to develop AD. The association
between pathological CSF findings and progression to
AD was independent of APOE genotype, age, gender,
and education. The combination of T-τ and Aβ-42/P-τ
ratio yielded closely similar results with a sensitivity
of 95% and a specificity of 87% [55]. CSF T-τ /Aβ-
42 and P- τ /Aβ-42 ratios were recently identified as
good biomarkers that predict future dementia also in
cognitively healthy old subjects [37].
Some studies have tried to identify non-CSF periph-
eral markers of MCI. Among those, platelet forms of
amyloid precursor protein have been proposed. At
two-year follow-up MCI subjects who converted to AD
showed a significant decrease of baseline platelet APP
forms ratio compared to nonconverters, with a sensitiv-
ity of 83% and a specificity of 71% [20].
Among genetic predictors, the APOE ε4 allele, the
only genetic factor associated with an increased risk
of sporadic AD [38], was described to be associated
with conversion from MCI to dementia. Data from the
Mayo Clinic cohort, which is a relatively young group,
demonstrated that APOE ε4 genotype is the best pre-
dictor of conversion to dementia [101]. These findings
were recently confirmed by a longitudinal cohort study
in which the presence of at least one APOE ε4 allele
affected the transition from cognitively normal aging
into amnestic MCI or into dementia [64]. According to
these data, APOE ε4 may represent a predictor of de-
mentia only for aMCI but not for other MCI subtypes.
TREATMENT AND PREVENTION
Early treatment of mild to moderate AD is associated
with a better response than late treatment [130], so it
is conceivable that treating MCI may be most effective
in delaying progression to AD. However, to date there
is no proven pharmacological approach for MCI. An-
tioxidants, including Ginkgo Biloba, selegiline and vi-
tamin E, have been proposed for delaying the progres-
sion to dementia, but their usefulness is unclear [80].
In randomized clinical trials, cholinesterase inhibitors
(donepezil, rivastigmine, and galantamine), antioxidant
(vitamin E), anti-inflammatory drugs (rofecoxib), and
nootropics (piracetam) failed to prevent progression of
MCI to dementia [58]. In a randomized clinical trial of
three years of observation,donepezil showed a transient
preventive effect after one year, particularly in subjects
who had at least one APOE ε4 allele, but efficacy was
lost at the end of the study [102], so evidence is not
strong enough for recommending its routine use [114].
Management of subjects with MCI is currently non
specific: control of vascular risk factors, treatment of a
concomitant condition such as depression or hypothy-
roidism, and reduction in the use of anticholinergic
drugs have been proposed [47]. Epidemiological data
suggests that moderate exercise and physical activity,
such as walking three times a week, are associated with
a lower risk of dementia [105]. According to these find-
ings, a randomized controlled trial examining the effect
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of a walking program and vitamin B supplementation
on the rate of cognitive decline in older adults with MCI
is currently ongoing [124]. In addition, recent data
suggest that an active and socially integrated lifestyle
in late life protects against dementia and AD [45]. In
the Bronx Aging Study, participation in cognitive ac-
tivities was associated with a lower risk of development
of MCI, even after excluding individuals at early stages
of dementia [125]. Since it seems evident that memory
and attention training is beneficial in normal elderly
persons [13] and in patients with early AD [29], cog-
nitive training may have a role in subjects with MCI in
slowing down further decline and should be explored in
future clinical trials. Encouraging results, in fact, have
been reported from uncontrolled studies [54]. Final-
ly, clinicians should pay close attention to control for
modifiable cardiovascular risk factors, including blood
pressure, diabetes, and lipid profile, all factors that have
been associated with an increased risk of dementia.
CONCLUSIONS
MCI is a syndrome at high risk for dementia and not
a definitive diagnosis of a disease. It represents a con-
dition with multiple sources of heterogeneity, includ-
ing clinical presentation, etiology, and prognosis. The
majority of data present in the literature refer to aMCI
and very few concern other subtypes of the condition.
According to these data, aMCI seems to represent an
early stage of AD, while the outcomes of the other MCI
forms are more heterogeneous.
It might be time to consider revisions of the ICD
and DSM to include specific diagnostic criteria for
MCI. Furthermore, an update of the NINCDS-ADRDA
criteria for AD should include a prodromal stage of
Alzheimer’s disease that defines MCI. Current crite-
ria for MCI should be updated to include restriction in
complex ADL. There is a need for sensitive tools able
to detect subtle modification in cognitive and functional
abilities also to implement a primary prevention trial in
non demented subjects. With this aim the Alzheimer’s
Disease Cooperative Study Instrument Committee has
recently developed new assessment instruments that
can be self-administered and/or do not require signifi-
cant involvement of professional staff [41].
The diagnostic and prognostic role of specific be-
havioral symptoms (i.e. depression), somatic condi-
tions and motor dysfunctions need to be better clarified.
There is not enough evidence to recommend specific
predictors for the conversion from MCI to AD. The
combined use of cognitive tests, APOE genotype, and
neuroimaging techniques is probably the best option
for prediction purposes, but further studies are need-
ed to define the sensitivity and specificity of this glob-
al approach for recommending its routine use at the
screening level.
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